Walmart Stock Falls After Oppenheimer Downgrade Cites Pharmacy Headwinds

Walmart (NYSE: WMT) shares slipped 1.2% in pre-market trading after analysts at Oppenheimer downgraded the stock, flagging concerns over the company's pharmacy operations and its current valuation.

Analyst Downgrade Details

Oppenheimer lowered its rating on Walmart to Perform from a previous Outperform, removing its $140 price target on the stock. The firm's downgrade, which comes just over two weeks before Walmart's scheduled Q2 earnings report on August 20, is based on several key factors.

The broker cited "meaningful top-line pressure" on Walmart's U.S. pharmacy segment stemming from the Inflation Reduction Act. Oppenheimer expects this to negatively impact the retailer's comparable-sales figures in the second quarter and potentially beyond.

Additional concerns highlighted by the firm include:

Ad

• The stock's premium valuation, which it believes leaves limited room for further upside.
• A view that consensus analyst forecasts are running ahead of the company's longer-term management guidance.
• A resulting "less compelling outperformance case" for the shares in the near term.

Market Reaction and Context

The downgrade contributed to Walmart's shares trading at $109.37 in the pre-market session. The stock's decline stood in contrast to the broader market, with S&P 500 futures up 1.48% and Dow futures gaining 1.32%, indicating the pressure on Walmart was company-specific.

The move compounds a recent pullback for the stock, which had already fallen from its 52-week high of $135.16. The weakness comes amid wider investor concerns about the health of consumer spending. Walmart CFO John David Rainey previously noted that shoppers could face increased financial strain in the second quarter as the benefit from elevated tax refunds fades.